StockData
Karyopharm Therapeutics Inc. logo

Karyopharm Therapeutics Inc. (KPTI) stock

KPTINasdaqPharmaceutical PreparationsFiscal year ends December 31Also trades as KPTIQ
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 13, 2026Score 1/30
$0.04−0.01 (-20.00%)

Close on Nov 9, 2026Market cap $1.16KP/E –Yield –

Karyopharm Therapeutics revenue

Revenue is the money a company takes in from selling its products and services, before any costs are deducted.

Karyopharm Therapeutics's revenue for the twelve months ending Jun 30, 2026 was $146.62M, up 6.8% year over year. For fiscal 2025 it was $146.07M, up 0.6% from the year before. Over ten years it grew 89.1% a year on average. The highest annual figure on record is $209.82M in fiscal 2021.

Annual revenue

PeriodPeriod endValueChange
FY2025Dec 31, 2025$146.07M+0.6%
FY2024Dec 31, 2024$145.24M-0.5%
FY2023Dec 31, 2023$146.03M-7.0%
FY2022Dec 31, 2022$157.07M-25.1%
FY2021Dec 31, 2021$209.82M+94.1%
FY2020Dec 31, 2020$108.09M+164.3%
FY2019Dec 31, 2019$40.89M+34.8%
FY2018Dec 31, 2018$30.34M+1790.1%
FY2017Dec 31, 2017$1.61M+942.2%
FY2016Dec 31, 2016$154.00K-38.4%
FY2015Dec 31, 2015$250.00K+9.2%
FY2014Dec 31, 2014$229.00K-40.8%
FY2013Dec 31, 2013$387.00K-39.0%
FY2012Dec 31, 2012$634.00K+317.1%
FY2011Dec 31, 2011$152.00K–

Quarterly revenue

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026$33.43M-11.9%
Q1 FY2026Mar 31, 2026$35.07M+16.8%
Q4 FY2025Dec 31, 2025$34.08M+11.6%
Q3 FY2025Sep 30, 2025$44.04M+13.6%
Q2 FY2025Jun 30, 2025$37.93M-11.4%
Q1 FY2025Mar 31, 2025$30.02M-9.4%
Q4 FY2024Dec 31, 2024$30.54M-9.5%
Q3 FY2024Sep 30, 2024$38.78M+7.7%
Q2 FY2024Jun 30, 2024$42.79M+13.9%
Q1 FY2024Mar 31, 2024$33.13M-14.4%
Q4 FY2023Dec 31, 2023$33.75M+0.5%
Q3 FY2023Sep 30, 2023$36.01M-0.4%
Q2 FY2023Jun 30, 2023$37.58M-5.3%
Q1 FY2023Mar 31, 2023$38.70M-18.8%
Q4 FY2022Dec 31, 2022$33.58M-73.4%
Q3 FY2022Sep 30, 2022$36.15M-4.1%
Q2 FY2022Jun 30, 2022$39.68M+75.6%
Q1 FY2022Mar 31, 2022$47.67M+104.9%
Q4 FY2021Dec 31, 2021$126.27M+259.7%
Q3 FY2021Sep 30, 2021$37.69M+76.7%
Q2 FY2021Jun 30, 2021$22.60M-32.6%
Q1 FY2021Mar 31, 2021$23.26M+28.2%
Q4 FY2020Dec 31, 2020$35.10M+94.0%
Q3 FY2020Sep 30, 2020$21.33M+62.2%
Q2 FY2020Jun 30, 2020$33.51M+253.0%
Q1 FY2020Mar 31, 2020$18.14M+11601.9%
Q4 FY2019Dec 31, 2019$18.10M+8684.5%
Q3 FY2019Sep 30, 2019$13.15M+5401.7%
Q2 FY2019Jun 30, 2019$9.49M-52.3%
Q1 FY2019Mar 31, 2019$155.00K-98.5%
Q4 FY2018Dec 31, 2018$206.00K-86.6%
Q3 FY2018Sep 30, 2018$239.00K–
Q2 FY2018Jun 30, 2018$19.89M+662933.3%
Q1 FY2018Mar 31, 2018$10.00M+14605.9%
Q4 FY2017Dec 31, 2017$1.53M+3163.8%
Q3 FY2017Sep 30, 2017$0-100.0%
Q2 FY2017Jun 30, 2017$3.00K–
Q1 FY2017Mar 31, 2017$68.00K–
Q4 FY2016Dec 31, 2016$47.00K–
Q3 FY2016Sep 30, 2016$48.00K–

More Karyopharm Therapeutics figures

See a number that looks wrong?